Search

Your search keyword '"A. Poglitsch A."' showing total 106 results
Start Over Author "A. Poglitsch A." Journal journal of hypertension
106 results on '"A. Poglitsch A."'

4. Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects

Author

Cruz-López, Edwyn O., primary, Ye, Dien, additional, Stolk, Daniel G., additional, Clahsen-van Groningen, Marian C., additional, van Veghel, Richard, additional, Garrelds, Ingrid M., additional, Poglitsch, Marko, additional, Domenig, Oliver, additional, Symakani, Rahi S. Alipour, additional, Merkus, Daphne, additional, Verdonk, Koen, additional, and Danser, A.H. Jan, additional

Published
2023
Full Text
View/download PDF

10. Blood pressure-independent renoprotection in diabetic rats treated with small interfering RNA targeting liver angiotensinogen

Author

Edwyn Omar Cruz Lopez, Liwei Ren, Estrellita Uijl, Marian C. Clahsen-Van Groningen, Richard Van Veghel, Ingrid M. Garrelds, Oliver Domenig, Marko Poglitsch, Ivan Zlatev, Timothy Rooney, Anne Kasper, Paul Nioi, Don Foster, A.H. Jan Danser, Internal Medicine, and Pathology

Subjects
SDG 3 - Good Health and Well-being, Physiology, Internal Medicine, Cardiology and Cardiovascular Medicine
Abstract

OBJECTIVE: Small interfering RNA (siRNA) targeting liver angiotensinogen (AGT) exerts beneficial effects on blood pressure and kidney function, but its effects in diabetes are still unknown. DESIGN AND METHOD: To address this, TGR(mREN2)27 rats (a model of angiotensin II-dependent hypertension) were made diabetic with streptozotocin for 18 weeks and treated with vehicle, AGT siRNA, the angiotensin receptor blocker valsartan, the ACE inhibitor captopril, valsartan + siRNA, or valsartan + captopril for the final 3 weeks. Arterial pressure was measured via radiotelemetry. RESULTS: Baseline mean arterial pressure (MAP) was 164 ± 1 mm Hg. Diabetes resulted in albuminuria, accompanied by glomerulosclerosis and podocyte effacement, without a further rise in MAP or a change in glomerular filtration rate. All treatments lowered MAP (by ~50 mm Hg) and cardiac hypertrophy identically. Treatment with siRNA resulted in the largest reduction in AGT, while in combination with valsartan AGT virtually disappeared. Only the dual treatment groups and captopril lowered circulating angiotensin II and aldosterone. No treatment affected renal AGT mRNA expression, confirming the liver-specificity of the siRNA. Yet, siRNA with or without valsartan, and valsartan + captopril, but not valsartan alone, or captopril alone, reduced renal angiotensin I and II. All treatments lowered albuminuria and proteinuria, while only siRNA with or without valsartan improved glomerulosclerosis and podocyte dysfunction. Multiple linear regression confirmed both mean arterial pressure and renal angiotensin II as independent determinants of albuminuria. CONCLUSIONS: In conclusion, AGT siRNA exerts renoprotection in diabetic TGR(mREN2)27 rats, and this relies, at least in part, on the suppression of renal angiotensin II formation from liver-derived AGT. Consequently, AGT siRNA may prove beneficial in human diabetic kidney disease.

Published
2022
Full Text
View/download PDF

12. BLOOD PRESSURE-INDEPENDENT RENOPROTECTION IN DIABETIC RATS TREATED WITH SMALL INTERFERING RNA TARGETING LIVER ANGIOTENSINOGEN

Author

Lopez, Edwyn Omar Cruz, primary, Ren, Liwei, additional, Uijl, Estrellita, additional, Clahsen-Van Groningen, Marian C., additional, Van Veghel, Richard, additional, Garrelds, Ingrid M., additional, Domenig, Oliver, additional, Poglitsch, Marko, additional, Zlatev, Ivan, additional, Rooney, Timothy, additional, Kasper, Anne, additional, Nioi, Paul, additional, Foster, Don, additional, and Danser, A.H. Jan, additional

Published
2022
Full Text
View/download PDF

16. Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex

Author

Teresa Maria Seccia, Maurizio Iacobone, Marko Poglitsch, Selene Prisco, Oliver Domenig, Gian Paolo Rossi, Francesca Torresan, Brasilina Caroccia, Paul Emmanuel Vanderriele, Livia Lenzini, and Maria Piazza

Subjects
Aldosterone synthase, medicine.medical_specialty, Hydrocortisone, Physiology, Proto-Oncogene Mas, chemistry.chemical_compound, Irbesartan, Internal medicine, Renin–angiotensin system, Internal Medicine, Medicine, Cytochrome P-450 CYP11B2, Humans, Receptor, Aldosterone, biology, business.industry, Activator (genetics), Adrenal cortex, Angiotensin II, Peptide Fragments, Endocrinology, medicine.anatomical_structure, chemistry, Angiotensin-converting enzyme 2, cardiovascular system, biology.protein, Adrenal Cortex, Angiotensin-Converting Enzyme 2, Angiotensin I, Cardiology and Cardiovascular Medicine, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug
Abstract

Objective The branch of the renin--angiotensin system constituting angiotensin-(1-7) [Ang-(1-7)], the Ang II type 2 receptor, the Mas receptors and the Ang-(1-7)-forming enzyme ACE-2, by counteracting the Ang II type 1 receptor (AT1R)-mediated effects, are held to be cardiovascular protective in several conditions. However, whether Ang-(1-7) and ACE-2 are detectable in human adrenocortical tissues and whether they affect aldosterone and cortisol biosynthesis was unknown. Methods We measured angiotensin peptides with liquid chromatography tandem-mass spectrometry and ACE-2 mRNA with digital droplet (dd)PCR in human aldosterone-producing adenoma (APA) and APA-adjacent tissue obtained from patients with primary aldosteronism. We also investigated the effects of Ang-(1-7) and the ACE-2 activator diminazene aceturate (DIZE) on aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) gene expression, in the absence or presence of the AT1R antagonist irbesartan, or of the MasR antagonist A779. Results APA and APA-adjacent adrenocortical tissues express ACE-2 mRNA and contain detectable amounts of Ang II and Ang-(2-8), but not of Ang I, Ang-(1-5), Ang (3-8) and Ang-(1-7). Ang-(1-7) did not blunt CYP11B1 and CYP11B2 mRNA both under unstimulated and under Ang II-stimulated conditions. At supraphysiological concentrations (10-4 mol/l), Ang-(1-7) stimulated both CYP11B1 and CYP11B2 mRNA via the AT1R. The ACE-2 activator DIZE increased by 1.5-fold ACE-2 mRNA but did not blunt Ang II- upregulated CYP11B1 and CYP11B2 expression. Conclusion These results do not support the hypothesis that the ACE-2/Ang-(1-7)/MasR axis play a protective role by counteracting enhanced aldosterone secretion in humans.

Published
2021

18. INHIBITION OF ACE C-DOMAIN AND NEPRILYSIN AS A NEW THERAPY IN HYPERTENSION

Author

Alves-Lopes, Rheure, primary, Montezano, Augusto, additional, Neves, Karla, additional, Harvey, Adam, additional, Rios, Francisco, additional, Arendse, Lauren, additional, Camargo, Livia, additional, Graham, Delyth, additional, Poglitsch, Marko, additional, Ehlers, Mario, additional, Sturrock, Edward, additional, and Touyz, Rhian, additional

Published
2021
Full Text
View/download PDF

19. DOCA-SALT DIMINISHES BRAIN RAS ACTIVITY IN PARALLEL WITH PLASMA AND RENAL RAS ACTIVITY – NO EVIDENCE FOR SELECTIVE BRAIN RAS ACTIVATION

Author

Uijl, Estrellita, primary, Ren, Liwei, additional, Colafella, Katrina M. Mirabito, additional, Poglitsch, Marko, additional, Domenig, Oliver, additional, Zlatev, Ivan, additional, Kim, Jae B., additional, Huang, Stephen, additional, Melton, Lauren, additional, Foster, Don, additional, and Danser, A.H. Jan, additional

Published
2021
Full Text
View/download PDF

23. INFLUENCE OF ANTIHYPERTENSIVE TREATMENT ON RAAS PEPTIDES IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS

Author

Vischer, Annina, primary, Kuster, Gabriela, additional, Twerenbold, Raphael, additional, Pfister, Otmar, additional, Zhou, Qian, additional, Villiger, Andrea, additional, Poglitsch, Marko, additional, Krähenbühl, Stephan, additional, Mayr, Michael, additional, Osswald, Stefan, additional, Haschke, Manuel, additional, and Burkard, Thilo, additional

Published
2021
Full Text
View/download PDF

28. Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex

Author

Caroccia, Brasilina, primary, Vanderriele, Paul-Emmanuel, additional, Seccia, Teresa Maria, additional, Piazza, Maria, additional, Lenzini, Livia, additional, Prisco, Selene, additional, Torresan, Francesca, additional, Domenig, Oliver, additional, Iacobone, Maurizio, additional, Poglitsch, Marko, additional, and Rossi, Gian Paolo, additional

Published
2021
Full Text
View/download PDF

30. DOCA-SALT DIMINISHES BRAIN RAS ACTIVITY IN PARALLEL WITH PLASMA AND RENAL RAS ACTIVITY – NO EVIDENCE FOR SELECTIVE BRAIN RAS ACTIVATION

Author

Stephen Huang, Ivan Zlatev, Don Foster, Estrellita Uijl, Jae B. Kim, Oliver Domenig, Lauren Melton, Liwei Ren, A.H. Jan Danser, Marko Poglitsch, and Katrina M Mirabito Colafella

Subjects
medicine.medical_specialty, Endocrinology, Physiology, business.industry, Internal medicine, Internal Medicine, medicine, Cardiology and Cardiovascular Medicine, business, Doca salt
Published
2021
Full Text
View/download PDF

31. REFERENCE RANGES AND CUT-OFF VALUES FOR SIMULTANEOUS MONITORING OF RAS BLOCKER EFFICACY AND SCREENING FOR SECONDARY HYPERTENSION USING RAAS TRIPLE-A PROFILING

Author

Peter P. Pramstaller, Cristian Pattaro, Luisa Foco, Marko Poglitsch, and Martin Gögele

Subjects
Oncology, Profiling (computer programming), medicine.medical_specialty, Physiology, business.industry, Internal medicine, Internal Medicine, Medicine, Secondary hypertension, Cardiology and Cardiovascular Medicine, business, medicine.disease
Published
2021
Full Text
View/download PDF

32. INHIBITION OF ACE C-DOMAIN AND NEPRILYSIN AS A NEW THERAPY IN HYPERTENSION

Author

Lauren B. Arendse, Francisco J. Rios, Edward D. Sturrock, Rhian M. Touyz, Mario R. W. Ehlers, Augusto C. Montezano, Livia L Camargo, Karla B Neves, Marko Poglitsch, Delyth Graham, Rheure Alves-Lopes, and Adam Harvey

Subjects
Physiology, business.industry, Internal Medicine, Medicine, Computational biology, Cardiology and Cardiovascular Medicine, business, Neprilysin, Domain (software engineering)
Published
2021
Full Text
View/download PDF

33. ACE2 AND ANGIOTENSIN-(1-7) AND ALDOSTERONE BIOSYNTHESIS IN HUMAN ADRENOCORTICAL TISSUES

Author

Paul Emmanuel Vanderriele, Brasilina Caroccia, Livia Lenzini, Oliver Domening, Teresa Maria Seccia, Marko Poglitsch, Maurizio Iacobone, Selene Prisco, Francesca Torressan, Gian Paolo Rossi, and Maria Piazza

Subjects
medicine.medical_specialty, Aldosterone, Angiotensin 1, Physiology, business.industry, chemistry.chemical_compound, Endocrinology, chemistry, Biosynthesis, Internal medicine, Internal Medicine, medicine, Cardiology and Cardiovascular Medicine, business
Published
2021
Full Text
View/download PDF

34. DISTRIBUTION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS) BIOMARKERS IN TREATED HYPERTENSIVE INDIVIDUALS FROM THE GENERAL POPULATION: THE CHRIS STUDY

Author

Luisa Foco, Martin Gögele, Marko Poglitsch, Cristian Pattaro, and Peter P. Pramstaller

Subjects
medicine.medical_specialty, education.field_of_study, Physiology, business.industry, Population, Endocrinology, Internal medicine, Renin–angiotensin system, Internal Medicine, medicine, Distribution (pharmacology), Cardiology and Cardiovascular Medicine, business, education
Published
2021
Full Text
View/download PDF

35. THE EFFECT OF RAMIPRIL ON THE ALDOSTERONE/RENIN RATIO AND THE ALDOSTERONE/ANGIOTENSIN II RATIO IN PATIENTS WITH PRIMARY ALDOSTERONISM

Author

Brett McWhinney, Marko Poglitsch, Diane Cowley, Michael Stowasser, Zeng Guo, Martin Wolley, and Jacobus P.J. Ungerer

Subjects
Ramipril, medicine.medical_specialty, Aldosterone renin, Aldosterone, Physiology, business.industry, medicine.disease, Angiotensin II, chemistry.chemical_compound, Endocrinology, Primary aldosteronism, chemistry, Internal medicine, Internal Medicine, medicine, In patient, Cardiology and Cardiovascular Medicine, business, medicine.drug
Published
2021
Full Text
View/download PDF

36. SCREENING OF PRIMARY ALDOSTERONISM WITH A NOVEL RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM TRIPLE-A ANALYSIS

Author

Silvia Monticone, Oliver Domenig, Paolo Mulatero, Fabrizio Buffolo, Jacopo Burrello, Martina Tetti, Alessio Pecori, and Marko Poglitsch

Subjects
medicine.medical_specialty, Endocrinology, Primary aldosteronism, Physiology, business.industry, Internal medicine, Renin–angiotensin system, Internal Medicine, medicine, Cardiology and Cardiovascular Medicine, business, medicine.disease
Published
2021
Full Text
View/download PDF

37. EFFECTS OF ACE INHIBITORS AND ANGIOTENSIN TYPE-1 RECEPTOR BLOCKERS ON ACE-2 EXPRESSION IN HUMAN ALVEOLAR EPITHELIAL CELLS

Author

Ilaria Caputo, Brasilina Caroccia, Teresa Maria Seccia, Marko Poglitsch, Oliver Domenig, and Gian Paolo Rossi

Subjects
Ramipril, Lung, Physiology, business.industry, Pharmacology, medicine.disease, Angiotensin II, Irbesartan, medicine.anatomical_structure, Angiotensin-converting enzyme 2, Renin–angiotensin system, Internal Medicine, medicine, Adenocarcinoma, cardiovascular diseases, Cardiology and Cardiovascular Medicine, Receptor, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug
Abstract

Objective: Angiotensin converting enzyme 2 (ACE-2) has regained widespread attention as the cellular receptor of SARS-CoV-2 virus that caused the COVID-19 pandemic. It was contended that ACE inhibitors (ACEis) and angiotensin type 1 receptor (AT1R) antagonists (ARBs) increase ACE2 expression in lung cells and their administration in Covid-19 patients could be detrimental and/ or constitute a potential risk factor. As there were no evidences supporting this hypothesis we investigated the effect of ACEis/ARBs on ACE2 expression in lung cells. Design and method: Calu-3 cells, epithelial cells derived from lung adenocarcinoma, were treated with 10 μM irbesartan (ARB), or 10 μM ramipril (ACEi) alone or in the presence of 100 nM Angiotensin II (Ang II) for 12 hours in serum-free media. After 12 hrs ACE2 mRNA expression was evaluated by Digital droplet (dd)PCR. Results: We found that Ang II increased by two-fold ACE2 mRNA copies (vehicle 792.7 ± 161.3 vs Ang II 1475 ± 319.9;p

Published
2021
Full Text
View/download PDF

38. THE EFFECT OF RAMIPRIL ON THE ALDOSTERONE/RENIN RATIO AND ALDOSTERONE/ANGIOTENSIN II RATIO IN PATIENTS WITH PRIMARY ALDOSTERONISM

Author

Michael Stowasser, Jacobus P.J. Ungerer, Diane Cowley, Zeng Guo, Brett McWhinney, Marko Poglitsch, and Martin Wolley

Subjects
Ramipril, medicine.medical_specialty, Aldosterone renin, Aldosterone, Physiology, business.industry, medicine.disease, Angiotensin II, chemistry.chemical_compound, Primary aldosteronism, Endocrinology, chemistry, Internal medicine, Internal Medicine, medicine, In patient, Cardiology and Cardiovascular Medicine, business, medicine.drug
Published
2019
Full Text
View/download PDF

40. ACE-S

Author

Domenig, O., primary, Ahmed, A.H., additional, Guo, Z., additional, Stoller, A., additional, Burkard, T., additional, Haschke, M., additional, Stowasser, M., additional, and Poglitsch, M., additional

Published
2019
Full Text
View/download PDF

41. AT1 RECEPTOR BLOCKADE AND AT2 RECEPTOR STIMULATION EFFECT ON THE RAS PEPTIDE LEVELS IN THE PREVENTION AND TREATMENT OF EXPERIMENTAL AUTOIMMUNE MYOCARDITIS (EAM) IN MALE LEW

Author

Thomas Unger, U. Kintcher, Ludovit Paulis, R. Rajkovicova, P. Schmerler, Oliver Domenig, Marko Poglitsch, Simona Trubacova, M. Steckelings, and E. Kashina

Subjects
Autoimmune myocarditis, At1 receptor blockade, Physiology, business.industry, Ras Peptide, Internal Medicine, Medicine, Pharmacology, Cardiology and Cardiovascular Medicine, business, Receptor stimulation
Published
2018
Full Text
View/download PDF

42. ACE-S

Author

Zeng Guo, A. H. Ahmed, Michael Stowasser, Oliver Domenig, Manuel Haschke, M. Poglitsch, Thilo Burkard, and A. Stoller

Subjects
Physiology, business.industry, Renin–angiotensin system, Internal Medicine, Medicine, Pharmacology, Cardiology and Cardiovascular Medicine, business
Published
2019
Full Text
View/download PDF

43. A11374 RAAS Triple A-Testing

Author

Poglitsch, Marko, primary, Schwager, Cornelia, additional, van Oyen, Dunja, additional, Ziegelmayer, Claudia, additional, and Domenig, Oliver, additional

Published
2018
Full Text
View/download PDF

48. A1728 Measurement of aldosterone

Author

Guo, Zeng, primary, Poglitsch, Marko, additional, McWhinney, Brett, additional, Ungerer, Jacobus, additional, Ahmed, Ashraf H., additional, Gordon, Richard, additional, Wolley, Martin, additional, and Stowasser, Michael, additional

Published
2018
Full Text
View/download PDF

50. A11374 RAAS Triple A-Testing

Author

Cornelia Schwager, Oliver Domenig, Dunja van Oyen, Claudia Ziegelmayer, and Marko Poglitsch

Subjects
Oncology, medicine.medical_specialty, Primary aldosteronism, Physiology, business.industry, Internal medicine, Lc ms ms, Internal Medicine, Medicine, Cardiology and Cardiovascular Medicine, business, medicine.disease
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results